Arrowhead Pharmaceuticals (0HI3.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
Arrowhead Pharmaceuticals remains unprofitable, as reflected by its negative EPS and PE ratio. The current valuation is therefore based on future expectations rather than demonstrated earnings power, which raises risk if clinical or partnership milestones disappoint.
Despite a 7.5% decline over the last month, Arrowhead’s stock is trading well above its 200-day moving average, signaling a strong longer-term uptrend. The RSI near 55 suggests neither overbought nor oversold conditions, pointing to a period of consolidation after recent gains.
Alternative data points suggest operational expansion and sustained professional interest in Arrowhead. Rising job openings and a large LinkedIn following support a constructive view on the company’s growth trajectory, even though consumer-facing social media growth is modest.
Arrowhead Pharmaceuticals presents a mixed picture: technically resilient and operationally expanding, but still fundamentally unprofitable and sensitive to execution risk. The stock’s strong position above its 200-day moving average and positive hiring trends are offset by ongoing losses and a recent price pullback.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
You don't hold 0HI3.L in your mock portfolio yet.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started